A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer.

Trial Profile

A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2013

At a glance

  • Drugs AVN 944; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Avalon Pharmaceuticals; Vertex Pharmaceuticals
  • Most Recent Events

    • 03 Aug 2011 Planned end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 09 Jan 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 May 2008 The company is on track to complete this trial in 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top